Hyundai Bioscience Co. Ltd (048410) — Cash Flow-to-Debt Ratio
Hyundai Bioscience Co. Ltd (048410) has a Cash Flow-to-Debt Ratio of -0.28x as of December 2025, meaning its operating cash flow of ₩-5.54 Billion could theoretically repay 0% of its total liabilities (₩20.01 Billion) in one year. See free cash flow generation of Hyundai Bioscience Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hyundai Bioscience Co. Ltd Cash Flow-to-Debt Ratio (2008–2025)
Historical debt coverage capacity for Hyundai Bioscience Co. Ltd across 14 annual periods. Also explore how fast is Hyundai Bioscience Co. Ltd growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Hyundai Bioscience Co. Ltd (2008–2025)
Year-by-year debt coverage analysis for Hyundai Bioscience Co. Ltd. For market capitalisation and broader financial context, see 048410 market cap.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.85x | ₩-17.05 Billion | ₩20.01 Billion | ▼ -1167.0% |
| 2024 | 0.08x | ₩2.26 Billion | ₩28.27 Billion | ▲ +110.0% |
| 2023 | -0.80x | ₩-6.01 Billion | ₩7.52 Billion | ▲ +56.1% |
| 2022 | -1.82x | ₩-16.54 Billion | ₩9.09 Billion | ▼ -6306.3% |
| 2021 | -0.03x | ₩-538.48 Million | ₩18.96 Billion | ▼ -115.6% |
| 2020 | 0.18x | ₩7.50 Billion | ₩41.09 Billion | ▼ -67.7% |
| 2019 | 0.57x | ₩9.18 Billion | ₩16.25 Billion | ▲ +52.7% |
| 2018 | 0.37x | ₩5.01 Billion | ₩13.52 Billion | ▲ +286.3% |
| 2017 | -0.20x | ₩-3.70 Billion | ₩18.61 Billion | ▼ -61.0% |
| 2016 | -0.12x | ₩-4.34 Billion | ₩35.17 Billion | ▼ -2756.0% |
| 2015 | 0.00x | ₩87.36 Million | ₩18.81 Billion | ▼ -96.1% |
| 2014 | 0.12x | ₩1.22 Billion | ₩10.32 Billion | ▼ -51.3% |
| 2011 | 0.24x | ₩3.97 Billion | ₩16.30 Billion | ▼ -12.7% |
| 2008 | 0.28x | ₩10.37 Billion | ₩37.17 Billion | — |